Neuroene is developing mitochondrial-protective small molecules for epilepsy, Parkinson's and mitochondrial diseases. Our lead clinical candidate has FDA Orphan Drug Designation for Dravet syndrome, a rare childhood epilepsy with striking efficacy as a monotherapy in many animal seizure models, and works as an adjunct with additive antiseizure activity with no adverse drug-drug effects so far. Our candidate is well-tolerated, brain-penetrating, fast-acting and targets a new mechanism of action (mitochondrial protection) that is differentiated and complementary to current antiseizure medications. We seek $10M for IND-enabling studies and Phase I trials. We previously won the 2022 BioHealth Capital Region pitch competition.